Table 3.

Past and present human clinical studies utilizing CF101 and CF102.

Disease	Phase	Primary endpoints	Refs.	Current status
Rheumatoid arthritis	2a	ACR20 response at week 12	[56]	Phase 2b
Psoriasis	2	Reduction in PASI score of at least 75% from Baseline (PASI 75) to the end of the 12 weeks treatment period	[57]	Phase 2/3
Dry eye syndrome	2	Improvement of 25% or more over baseline at week 12 in tear film BUT or in superficial punctate keratitis as assessed by either FS or ST1 results	[60]	Phase 3
Hepatocellular carcinoma	1/2	To determine the safety, tolerability, dose-limiting toxicities, maximum tolerated dose, recommended Phase 2 dose and to assess the repeat-dose pharmacokinetic behavior of orally administered CF102		Ongoing
Hepatitis C virus infection	1/2	To determine the safety and tolerability of 15 days of orally administered CF102 in patients with chronic hepatitis C genotype 1, to assess the effects on HCV load during 24 weeks and to assess the repeat-dose pharmacokinetic behavior of CF102		Ongoing

FS = fluorescein staining ST1 = Schirmer shear test 1